Trial Profile

Long-term Safety and Tolerability of TAK-881 in Subjects With Primary Immunodeficiency Diseases (PIDD)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary)
Indications Primary immunodeficiency diseases
Focus Adverse reactions; Registrational
Sponsors Takeda

Most Recent Events

08 Nov 2024 Status changed from not yet recruiting to recruiting.
01 Jul 2024 Planned End Date changed from 7 May 2027 to 15 Jan 2029.
01 Jul 2024 Planned primary completion date changed from 7 May 2027 to 15 Jan 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com